|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wood LD, Canto MI, Jaffee EM and Simeone
DM: Pancreatic cancer: Pathogenesis, screening, diagnosis, and
treatment. Gastroenterology. 163:386–402. e12022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakamura M, Okano H, Blendy JA and Montell
C: Musashi, a neural RNA-binding protein required for Drosophila
adult external sensory organ development. Neuron. 13:67–81. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sheng W, Shi X, Lin Y, Tang J, Jia C, Cao
R, Sun J, Wang G, Zhou L and Dong M: Musashi2 promotes EGF-induced
EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling. J Exp Clin
Cancer Res. 39:162020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong P, Xiong Y, Hanley SJB, Yue J and
Watari H: Musashi-2, a novel oncoprotein promoting cervical cancer
cell growth and invasion, is negatively regulated by p53-induced
miR-143 and miR-107 activation. J Exp Clin Cancer Res. 36:1502017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kharas MG, Lengner CJ, Al-Shahrour F,
Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R,
et al: Musashi-2 regulates normal hematopoiesis and promotes
aggressive myeloid leukemia. Nat Med. 16:903–908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kudinov AE, Deneka A, Nikonova AS, Beck
TN, Ahn YH, Liu X, Martinez CF, Schultz FA, Reynolds S, Yang DH, et
al: Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins
to promote non-small cell lung cancer (NSCLC) metastasis. Proc Natl
Acad Sci USA. 113:6955–6960. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sheng W, Dong M, Chen C, Li Y, Liu Q and
Dong Q: Musashi2 promotes the development and progression of
pancreatic cancer by down-regulating Numb protein. Oncotarget.
8:14359–14373. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sheng W, Dong M, Chen C, Wang Z, Li Y,
Wang K, Li Y and Zhou J: Cooperation of Musashi-2, Numb, MDM2, and
P53 in drug resistance and malignant biology of pancreatic cancer.
FASEB J. 31:2429–2438. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang S, Li GX, Tan CC, He R, Kang LJ, Lu
JT, Li XQ, Wang QS, Liu PF, Zhai QL and Feng YM: FOXF2 reprograms
breast cancer cells into bone metastasis seeds. Nat Commun.
10:27072019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He W, Kang Y, Zhu W, Zhou B, Jiang X, Ren
C and Guo W: FOXF2 acts as a crucial molecule in tumours and
embryonic development. Cell Death Dis. 11:4242020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Milewski D, Pradhan A, Wang X, Cai Y, Le
T, Turpin B, Kalinichenko VV and Kalin TV: FoxF1 and FoxF2
transcription factors synergistically promote rhabdomyosarcoma
carcinogenesis by repressing transcription of p21Cip1 CDK
inhibitor. Oncogene. 36:850–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hauptman N, Jevšinek Skok D, Spasovska E,
Boštjančič E and Glavač D: Genes CEP55, FOXD3, FOXF2, GNAO1, GRIA4,
and KCNA5 as potential diagnostic biomarkers in colorectal cancer.
BMC Med Genomics. 12:542019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Zhang C, Sang L, Huang L, Du J
and Zhao X: FOXF2 inhibits proliferation, migration, and invasion
of Hela cells by regulating Wnt signaling pathway. Biosci Rep.
38:BSR201807472018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang A, Jin C, Li H, Qin Q and Li L:
LncRNA ADAMTS9-AS2 regulates ovarian cancer progression by
targeting miR-182-5p/FOXF2 signaling pathway. Int J Biol Macromol.
120:1705–1713. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lo PK: FOXF2 differentially regulates
expression of metabolic genes in non-cancerous and cancerous breast
epithelial cells. Trends Diabetes Metab. 1:10.15761/TDM.1000103.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lo PK, Lee JS, Liang X and Sukumar S: The
dual role of FOXF2 in regulation of DNA replication and the
epithelial-mesenchymal transition in breast cancer progression.
Cell Signal. 28:1502–1519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pei H, Li L, Fridley BL, Jenkins GD,
Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects
cancer cell response to chemotherapy by negatively regulating Akt.
Cancer Cell. 16:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xia G, Wang H, Song Z, Meng Q and Huang X
and Huang X: Gambogic acid sensitizes gemcitabine efficacy in
pancreatic cancer by reducing the expression of ribonucleotide
reductase subunit-M2 (RRM2). J Exp Clin Cancer Res. 36:1072017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou Q and Gallo JM: Differential effect
of sunitinib on the distribution of temozolomide in an orthotopic
glioma model. Neuro Oncol. 11:301–310. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higashimori A, Dong Y, Zhang Y, Kang W,
Nakatsu G, Ng SSM, Arakawa T, Sung JJY, Chan FKL and Yu J: Forkhead
Box F2 suppresses gastric cancer through a novel
FOXF2-IRF2BPL-β-catenin signaling axis. Cancer Res. 78:1643–1656.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Torphy RJ, Fujiwara Y and Schulick RD:
Pancreatic cancer treatment: Better, but a long way to go. Surg
Today. 50:1117–1125. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu H, Wei M, Xu J, Hua J, Liang C, Meng
Q, Zhang Y, Liu J, Zhang B, Yu X and Shi S: PARP inhibitors in
pancreatic cancer: Molecular mechanisms and clinical applications.
Mol Cancer. 19:492020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heinrich S and Lang H: Neoadjuvant therapy
of pancreatic cancer: Definitions and benefits. Int J Mol Sci.
18:16222017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang T, Wan JG, Liu JB and Deng M:
MiR-200c inhibits metastasis of breast tumor via the downregulation
of Foxf2. Genet Mol Res. 16:gmr160389712017. View Article : Google Scholar
|
|
27
|
Kundu ST, Byers LA, Peng DH, Roybal JD,
Diao L, Wang J, Tong P, Creighton CJ and Gibbons DL: The miR-200
family and the miR-183~96~182 cluster target Foxf2 to inhibit
invasion and metastasis in lung cancers. Oncogene. 35:173–186.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen J, Ding J, Wang Z, Zhu J, Wang X and
Du J: Identification of downstream metastasis-associated target
genes regulated by LSD1 in colon cancer cells. Oncotarget.
8:19609–19630. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou L, Sheng W, Jia C, Shi X, Cao R, Wang
G, Lin Y, Zhu F, Dong Q and Dong M: Musashi2 promotes the
progression of pancreatic cancer through a novel ISYNA1-p21/ZEB-1
pathway. J Cell Mol Med. 24:10560–10572. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li T, Huang S, Yan W, Zhang Y and Guo Q:
FOXF2 regulates PRUNE2 transcription in the pathogenesis of
colorectal cancer. Technol Cancer Res Treat.
21:153303382211187172022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu JT, Tan CC, Wu XR, He R, Zhang X, Wang
QS, Li XQ, Zhang R and Feng YM: FOXF2 deficiency accelerates the
visceral metastasis of basal-like breast cancer by unrestrictedly
increasing TGF-β and miR-182-5p. Cell Death Differ. 27:2973–2987.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Choi HY, Seok J, Kang GH, Lim KM and Cho
SG: The role of NUMB/NUMB isoforms in cancer stem cells. BMB Rep.
54:335–343. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colaluca IN, Tosoni D, Nuciforo P,
Senic-Matuglia F, Galimberti V, Viale G, Pece S and Di Fiore PP:
NUMB controls p53 tumour suppressor activity. Nature. 451:76–80.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pece S, Serresi M, Santolini E, Capra M,
Hulleman E, Galimberti V, Zurrida S, Maisonneuve P, Viale G and Di
Fiore PP: Loss of negative regulation by Numb over Notch is
relevant to human breast carcinogenesis. J Cell Biol. 167:215–221.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tian HP, Lun SM, Huang HJ, He R, Kong PZ,
Wang QS, Li XQ and Feng YM: DNA methylation affects the
SP1-regulated transcription of FOXF2 in breast cancer cells. J Biol
Chem. 290:19173–19183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu ZH, Lun SM, He R, Tian HP, Huang HJ,
Wang QS, Li XQ and Feng YM: Dual function of MAZ mediated by FOXF2
in basal-like breast cancer: Promotion of proliferation and
suppression of progression. Cancer Lett. 402:142–152. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Meyer-Schaller N, Heck C, Tiede S, Yilmaz
M and Christofori G: Foxf2 plays a dual role during transforming
growth factor beta-induced epithelial to mesenchymal transition by
promoting apoptosis yet enabling cell junction dissolution and
migration. Breast Cancer Res. 20:1182018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dai W, Zeng W and Lee D: lncRNA MCM3AP-AS1
inhibits the progression of colorectal cancer via the
miR-19a-3p/FOXF2 axis. J Gene Med. 23:e33062021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Safe S, Shrestha R, Mohankumar K, Howard
M, Hedrick E and Abdelrahim M: Transcription factors specificity
protein and nuclear receptor 4A1 in pancreatic cancer. World J
Gastroenterol. 27:6387–6398. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maity G, Haque I, Ghosh A, Dhar G, Gupta
V, Sarkar S, Azeem I, McGregor D, Choudhary A, Campbell DR, et al:
The MAZ transcription factor is a downstream target of the
oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion
via CRAF-ERK signaling. J Biol Chem. 293:4334–4349. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yu X, Zheng Q, Zhang Q, Zhang S, He Y and
Guo W: MCM3AP-AS1: An indispensable cancer-related LncRNA. Front
Cell Dev Biol. 9:7527182021. View Article : Google Scholar : PubMed/NCBI
|
